AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners 

WASHINGTON, – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech. Continue reading

Roche to invest USD 50 billion in pharmaceuticals and diagnostics in the United States over the next five years

  • USD 50 billion commitment includes new state-of-the art research and development (R&D) sites, new and expanded manufacturing facilities in Indiana, Pennsylvania, Massachusetts and California and an additional site location to be announced soon
  • Investments will create more than 12,000 new jobs: 1,000 at Roche and more than 11,000 in support of new US manufacturing capabilities
  • Roche already has a significant existing US presence with more than 25,000 employees, 15 R&D centres and 13 manufacturing sites

Continue reading

Delta Development Team Selected for $1.57M TACFI Opportunity to Advance Total Blood System (TBS)

Tucson, Arizona – April 17, 2025 – Delta Development Team (DDT) is proud to announce that it has been selected for a $1.57 million Tactical Funding Increase (TACFI) opportunity by AFWERX, the innovation arm of the Department of the Air Force and a directorate within the Air Force Research Laboratory.  The phase IIB award represents a partnership between DDT, AFWERX, the 59th Medical Wing’s Office of the Chief Scientist, the Center for Sustainment of Trauma and Readiness Skills (C-STARS), and Air Mobility Command. This funding will accelerate the development of DDT’s groundbreaking Total Blood System (TBS), a revolutionary technology poised to transform blood management for enroute military care, battlefield distribution, and prehospital blood transfusion programs for emergency healthcare.Continue reading

Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System

    • Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes.
    • Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes.
    • For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system.

Continue reading